Developments in the treatment of uveitis

Bibliography

• ROTHOVA A, SUTTORP-VAN SCHULTEN MS, TREFFERS WF, KIJLSTRA A: Causes and frequency of blindness in patients with intraocular inflammatory disease. Br j Ophthalmol (1996) 80:332–336.
   PubMed Web of Science ®Google Scholar
• NUSSENBLATT RB. NATIONAL INSTITUTE OF HEALTH: Report of the National Advisory Eye Council support for visual research. US Department of Health, Education and Welfare, Washington DC, USA (1976).
   Google Scholar
• RAIZMAN M: Coticosteroid therapy of eye disease. Arch. Ophthalmol (1996) 114:1000–1001.
   PubMed Web of Science ®Google Scholar
• RIORDAN-EVA P, LIGHTMAN S: Orbital floor steroid injection in the treatment of uveitis. Eye (1994) 8:66–69.
   PubMed Web of Science ®Google Scholar
• GRAHAM RO, PEYMAN GA: Intravitreal injection of dexamethasone: treatment of experimentally induced endophthalmitis. Arch. Ophthalmol (1974) 92:149–154.
   PubMed Web of Science ®Google Scholar
• DIAMOND JG: Intraocular management of endophthalmitis: a systemic approach. Arch. Ophthalmol (1991) 99:96–99.
   Google Scholar
• MAXWELL DP Jr, BRENT BD, DIAMOND JG et al.: Effect of intravitreal dexamethasone on ocular histopathology in a rabbit model if endophthalmitis. Ophthalmology (1991) 98:1370–1375.
   PubMed Web of Science ®Google Scholar
• KWAK HW, D'MICO DJ: Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch. Ophthalmol (1992) 110:259–266.
   PubMed Web of Science ®Google Scholar
• KELLER N, JAMIESON L, OLIEKNIK 0 et al.: Efficacy of intravitreal dexamethasone in experimental uveitis: effect of drug delivery in a biodegradable polymer. Invest Ophthalmol Vis. Sci.(1986) 110:248.
   Google Scholar
• CHENG C, BERGER AS, PEARSON PA et al.: Intravitreal sustained release dexamethasone device in the treatment of experimental uveitis. Invest. Ophthalmol. Vis. Sci. (1995) 36:442–453.
   PubMed Web of Science ®Google Scholar
• ENYEDI LB, PEARSON PA, ASHTON P et al.: An intravitreal device providing sustained release of cyclosporine and dexamethasone. Cun: Eye Res. (1996) 15:549–557.
   PubMed Web of Science ®Google Scholar
• JAFFE GJ, YANG CH, GUO H etal.: Safety and pharmacokinetics of an intravitreal fluocinoloneacetonide sustained delivery device. Invest. Ophthalmol. Vis. Sci. (2000) 41:3569–3575.
   Google Scholar
• JAFFE GJ, BEN-HUN J, GUO J ETAL: Flucinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology (2000) 107:2024–2033.
   PubMed Web of Science ®Google Scholar
• YOUNG S, LARKIN G, BRANLEY M, LIGHTMAN S: Safety and efficacy of introcular triamcinolone for cystoid macular oedema in uveitis. Clin. Esp. Ophthalmol. (2001) 29:2–6.
   PubMed Web of Science ®Google Scholar
• YAZICI J, PAZARLI H, BARNES CG et al.:A controlled trial of azathioprine in Behcet's syndrome. N Engl. J. Med. (1990) 322:281–285.
   PubMed Web of Science ®Google Scholar
• HOLZ FG, KRASTEL H, BREITBART A et al.: Low dose methotrexate therapy in non-infectious uveitis resistant to corticosteroids. Ger. j Ophthalmol. (1992) 1:142–144.
   PubMedGoogle Scholar
• SHAH SS, LOWDER CY, SCHMITT MA et al.: Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology (1992) 99:1419–1423.
   PubMed Web of Science ®Google Scholar
• DEV S, McCALLUM RM, JAFFE GJ: Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology (1999) 106:111–118.
   PubMed Web of Science ®Google Scholar
• SAMSON CM, WAHEED N, BALTATZIS S, FOSTER CS: Methotrexate therapy for chronic non-infectious uveitis: analysis of a case series of 160 patients. Ophthalmology (2001) 108:1134–1139.
   PubMed Web of Science ®Google Scholar
• BOM S, ZAMIRI P, LIGHTMAN S: Use of methotrexate in the management of sight-threatening uveitis. OcuL ImmurroL (2001) 9:35–40.
   PubMed Web of Science ®Google Scholar
• WALLACE CA: The use of methotrexate inchildhood rheumatic disease. Arthritis Rheum. (1998) 41:381–391.
   PubMed Web of Science ®Google Scholar
• GIANNINI EH, BREWER EJ, KUZMINA N et al.: Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-U.S.S.R double-blind, placebo-controlled trial. N Engl. J. Med. (1992) 326:1043–1049.
   Google Scholar
• TUGAL-TUTKAN I, HAVRLIKOVA K, POWER WJ, FOSTER CS: Changing patterns in uveitis of childhood. Ophthalmology (1996) 103:375–383.
   PubMed Web of Science ®Google Scholar
• PLAZ KP, SOLLINGER HW, HULLETT DA et al.: RS-61443, a new potent immunosuppressive agent. Transplantation (1990) 51:27–31.
   Web of Science ®Google Scholar
• ALLISON AC, EUGUI EM: Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. ImmurroL Rev (1993) 136:5–28.
   Google Scholar
• CHANAUD NP 111, VISTICA BE EUGUI E eta].: Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism. Exp. Eye Res. (1995) 61:429–434.
   Google Scholar
• KILMARTIN DJ, FORRESTER JV, DICK AD: Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet (1998) 106:370–374.
   Google Scholar
• LARKIN G, LIGHTMAN S: Mycophenolate mofetil: a useful immunosuppressive in inflammatory eye disease. Ophthalmology (1999) 106:370–374.
   PubMed Web of Science ®Google Scholar
• LAO CH, CROMER M, LIGHTMAN SL: Use of mycofenolate mofetil in long-term control of ocular inflammatory diseases. JO VS (2001) ARVO Abstract Vol.42, No.4:S464.
   Google Scholar
• LIPSKY JJ: Mycophenolate mofetil. Lancet (1996) 348:1357–1359.
   PubMed Web of Science ®Google Scholar
• SMOLEN JS, KALDEN JR, SCOTT DL et al.: Efficacy and safety of leflunomide compared with placebo and sulfasalazine in active rheumatoid arthritis: a double-blind, randomised, multicenter trial: European Leflunomide Study Group. Lancet (1999) 353:259–266.
   PubMed Web of Science ®Google Scholar
• FOX RL, HERMANN ML, FRANGOU CG eta].: Mechanism of action for leflunomide in rheumatoid arthritis. OM. ImmurroL (1999) 93:198–208.
   Google Scholar
• ROBERTSON SM, LANG LS: Leflunomide: inhibition of S-antigen induced autoimmune uveitis in Lewis rats. Agents Actions (1994) 42(3-4):167–172.
   PubMedGoogle Scholar
• NUSSENBLATT RB, PALESTINE AG, CHAN CC: Cyclosporine A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am. j OphthalmoL (1983) 96:275–282.
   PubMed Web of Science ®Google Scholar
• MASUDA K, NAKAJIMA A, URAYAMA A et al.: Double-masked trial of cyclosporine versus colchicine and long-term open study of cyclosporine in Behcet's disease. Lancet (1989) 1:1093–1096.
   PubMed Web of Science ®Google Scholar
• GERBER DA, BONHAM CA, THOMSON AW: Immunosuppressive agents: recent developments in molecular action and clinical application. Tramplani Proc. (1998) 30:1573–1579.
   PubMed Web of Science ®Google Scholar
• NUSSENBLATT RB, PALESTINE AG, CHAN CC et al.: Randomized double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am. J. OphthalmoL (1991) 112:138–146.
   PubMed Web of Science ®Google Scholar
• NUSSENBLATT RB, DINNING WJ, FUJIKAWA LS et al.: Local cyclosporine therapy for experimental uveitis in rats. Arch. OphthalmoL (1985) 103:1559–1562.
   PubMed Web of Science ®Google Scholar
• JAFFE GJ, YANG C, WANG X et al.: Intravitreal sustained-released cyclosporine in the treatment of experimental uveitis. Ophthalmology (1998) 105:46–56.
   PubMed Web of Science ®Google Scholar
• PEARSON PA, JAFFE GJ, MARTIN DF et al.: Evaluation of a delivery system providing long-term release of cyclosporine. Arch. Ophthalmol (1996) 114:311–317.
   PubMed Web of Science ®Google Scholar
• SUZUKI N, KANEKO S, ICHINO M et al.: In vivo mechanisms for the inhibition of T lymphocyte activation by long-term therapy with tacrolimus (PK-506). Arthritis Rheum. (1997) 40:1157–1167.
   PubMed Web of Science ®Google Scholar
• FUNG JJ, ABU-ELMAGD K, JAIN AB et al.: A randomized trial of primary liver transplantation under immunosuppression with FK506 versus cyclosporine. Transplarri Proc. (1991) 23:2977–2983.
   PubMed Web of Science ®Google Scholar
• FUNG JJ, ELIASZIW M, TODO S et al.: The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. j Am. Coll. &mg. (1996) 183:117–125.
   PubMed Web of Science ®Google Scholar
• MOCHIZUKI M, MASUDA K, SAKANE T et al.: A clinical trial of FK 506 in refractory uveitis. Am. j OphthalmoL (1993) 115:763–769.
   PubMed Web of Science ®Google Scholar
• ISHIOKA M, OHNO S, NAKAMURA S et al.: FK 506 treatment of non-infectious uveitis. Am. J. OphthalmoL (1994) 118:723–729.
   PubMed Web of Science ®Google Scholar
• KILMARTIN DJ, FORRESTER JV, DICKAD. Tacrolimus (FK 506) in failed cyclosporine therapy in endogenous posterior uveitis. OcuL Immurrol. Inllamm. (1998) 6:101–109.
   Google Scholar
• SLOPER CM, POWELL RJ, DUA HS: Tacrolimus (FK 506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology (1999) 106:723–728.
   PubMed Web of Science ®Google Scholar
• FREEMAN EE, GROSSKREUTZ CL: The effects of FK 506 on retinal ganglion cells after optic nerve crush. Invest. OphthalmoL Vis. Sci. (2000) 41:1111–1115.
   PubMed Web of Science ®Google Scholar
• KIKUCHI M, KASHII S, MANDAI M et al.: Protective effects of FK 506 against glutamate-induced neurotoxicity in retinal cell culture. Invest. Ophthalmol. Vis. Sci. (1998) 39:1227–1232.
   PubMed Web of Science ®Google Scholar
• WHITCUP SM, PLEYER U, LAI JC eta].: Topical liposomes-encapsulated FK 506 for the treatment of endotoxin-induced uveitis. OcuL ImmurroL Inllamm. (1998) 6:51–56.
   Google Scholar
• ROBERGE FG, XU D, CHAN CC et al.: Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction. Curr. Eye Res. (1993) 12:197–203.
   PubMed Web of Science ®Google Scholar
• OHIA EO, MANCINO M, KULKARNI PS: Effects of steroids and immunosuppressive drugs on endotoxin-uveitis in rabbits. ..J. OcuL PharmacoL (1992) 8(4):295–307.
   PubMedGoogle Scholar
• MARTIN DF, DeBARGE LR, NUSSENBLATT RB, CHAN CC, ROBERGE FG: Synergistic effect of rapamycin and cyclosporine A in the treatment of experimental autoimmune uveoretinitis. j ImmurroL (1995) 154:922–927.
   Web of Science ®Google Scholar
• IKEDA E, HIKITA N, ETO K, MOCHIZUKI M: Tacrolimus-rapamycin combination therapy for experimental autoimmune uveoretinitis. fpri. OphthalmoL (1997) 46:396–402.
   Google Scholar
• TRICOULIS D: Treatment of Behcet's disease with chlorambucil. Br j OphthalmoL (1976) 60:55–.
   PubMed Web of Science ®Google Scholar
• ODUFFY JD, ROBERTSON DM, GOLDSTEIN NP: Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet's disease. Am. j Med. (1984) 76:75–84.
   PubMed Web of Science ®Google Scholar
• MAMO JG: Treatment of Behcet's disease 65 with chlorambucil . A follow-up report. Arch. Ophthalmol (1976) 94:580–583.
   PubMed Web of Science ®Google Scholar
• TESSLER HH, JENNINGS T: High-doseshort-term chlorambucil for intractable sympathetic ophthalmia and Behcet's disease. Br .j Ophthalmol (1990) 74:353–357.
   PubMed Web of Science ®Google Scholar
• BANGERTER M, GRIESSHAMMER M, vTIRPITZ C et al.: Myelodysplatic syndrome with monosomy 7 after immunosuppressive therapy in Behcet's disease. Scam/. j Rheumatol (1992) 28:117–119.
   Google Scholar
• PALMER RG, DORE CJ, DENMAN AM: Chlorambucil-induced chromosome damage to human lymphocytes is dose-dependent and cumulative. Lancet (1984) 1:246–249.
   PubMed Web of Science ®Google Scholar
• TABBARA KF: Chlorambucil in Behcet's disease. Ophthalmology (1983) 90:906–908.
   PubMed Web of Science ®Google Scholar
• WESCHLER B, BODAGHI B, HUONG DL et al.: Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet disease. Owl Immunol Inllamm. (2000) 8: 293–301.
   PubMed Web of Science ®Google Scholar
• KOTTER I, ECKSTEIN AK, STUBINGER N, ZIERHUT M: Treatment of ocular symptoms of Behcet disease with interferon 2a:a pilot study. Br I Ophthalmol (1998) 82:488–494.
   PubMed Web of Science ®Google Scholar
• BECKER MD, ROSENBAUM JT: Currentand future trends in the use of immunosuppressive agents in patients with uveitis. Curr. Opin. Ophthalmol (2000) 11:472–477.
   PubMedGoogle Scholar
• MAINI RN, TAYLOR PC: Anti-cytokine therapy for rheumatoid arthritis. Arnim Rev Med. (2000) 52:207–229.
   Google Scholar
• LOVELL DJ, GIANNI EH, REIFF A etal.: Etanercept in children with polyarticular juvenile rheumatoid arthritis: Paediatric Rheumatology Collaborative Study Group. N Engl. I Med. (2000) 342:763–769.
   Google Scholar
• WEINBLATT ME, KRAMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumour necrosis factor receptor Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl. I Med. (1999) 340:1936–1404.
   Google Scholar
• RUSSELL E, ZEIIHEN M, WERGIN S et al.: Patients receiving etanercept may develop antibodies that interfere with monoclonal antibody laboratory assays. Arthritis Rheum. (2000) 43:944.
   PubMed Web of Science ®Google Scholar
• MURPHY FT, ENZENAUER RJ, BATTAFARANO DF et al.: Etanercept associated injection site reactions. Arch. Dermatol (2000) 136:556–557.
   PubMed Web of Science ®Google Scholar
• REIFF A, TAKEI S, SADEGHI S etal.: Etanercept therapy in children with treatment resistant uveitis. Arthritis Rheum. (2001) 44:1411–1415.
   Google Scholar
• MAINI R, St CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase 111 trial: ATTRACT Study Group. Lancet (1999) 354: 1932-1939.
   Google Scholar
• GOOSENS PH, VERBURG RJ, BREEDVELD FC: Remission of Behcet's syndrome using tumour necrosis factor alpha blocking therapy. Ann. Rheum. Dis. (2001) 60:637.
   PubMed Web of Science ®Google Scholar
• ROBERTSON LP, HICLING P: Treatment of recalcitrant orogenital ulceration of Behcet's syndrome with infliximab. Rheumatology (2001) 40:473–474.
   PubMed Web of Science ®Google Scholar
• HASSARD PV, BINDER SW, NELSON V, VASIILIAUSKAS EA: Anti-tumour necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. Gastroenterology (2001) 120:995–999.
   PubMed Web of Science ®Google Scholar
• ROSENBAUM JT, HAN YB, PARK JM etal.: Tumour necrosis factor-alpha is not essential in endotoxin induced eye inflammation: studies in cytokine receptor deficient mice. j Rheumatol (1996) 25:2408–2416.
   Google Scholar
• DICK AD, DUNCAN 1, HALE G etal.: Neutralising TNF alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. Autoimmunig, (1998) 11:255–264.
   Google Scholar
• VICENTI E KIRKMAN R, LIGHTS et al.: Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation: daclizumab triple therapy group. N Engl. J Med. (1998) 338:161–165.
   PubMed Web of Science ®Google Scholar
• NUSSENBLATT RB, FORTIN E, SCHIFFMAN R et al.: Treatment of non-infectious intermediate and posterior uveitis with humanised antiTac mAb: a phase 1/11 clinical trial. Proc. Nati Acad. ScL USA (1999) 96:7462–7466.
   PubMed Web of Science ®Google Scholar
• DICK AD, MEYER P, JAMES T et al.: Campath- IH therapy in refractory ocular inflammatory disease. Br. I Ophthalmol (2000) 84:107–109.
   PubMed Web of Science ®Google Scholar
• ROSENBAUM JT, GEORGE RK, GORDON C: The treatment of refractory uveitis with intravenous immunoglobulin. Am. J. Ophthalmol (1999) 127:545–549.
   PubMed Web of Science ®Google Scholar
• LEHOANG P, CASSOUX N, GEORGE F, KULMANN N, KAZATCHKINE MD: Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Immunol Inllamm. (2000) 8:49–57.
   PubMed Web of Science ®Google Scholar
• MATTINGLY J, WAKSMAN B: Immunologic suppression after oral administration of antigen. Specific suppresser cells found in rat Peyer's patches after oral administration of sheep erythrocytes and their systemic migration. I Immunol (1978) 121:1878.
   Google Scholar
• NUSSENBLATT RB, WHITCUP SM, de SMET MD et al: Intraocular inflammatory disease (uveitis) and the use of oral tolerence. Ann. NY Acad. Sci. (1996) 778:325–337.
   PubMed Web of Science ®Google Scholar
• THURAU SR, CHAN C, NUSSENBLATT RB et al Oral tolerence in a murine model of relapsing experimental auto immune uveitis (EAU): induction of projective tolerence in primed animals. Clin. Exp. Immunol (1997) 109:370–37.
   PubMed Web of Science ®Google Scholar
• NUSSENBLATT RB, GERY I, WEINER HL et al.: Treatment of uveitis by oral administration of retinal antigens: results of a phase 1/11 randomised masked trial. Am. Ophthalmol (1997) 123:583–592.
   PubMed Web of Science ®Google Scholar
• THURAU SR, DIEDRICHS-MOHRING M, FRICKE H, ARBOGAST S, WILDNER G: Molecular mimicry as a therapeutic approach for an autoimmune disease: oral treatment of uveitis patients with an MHC-peptide crossreactive with autoantigen-first results. Immunol Lett. (1999) 68:205–212.
   PubMed Web of Science ®Google Scholar
• DICK AD, AZIM M, FORRESTER JV: Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporine A. Br I Ophthalmol (1997) 81:1107–1112.
   PubMed Web of Science ®Google Scholar
• HONG JC, KAHAN BD: Sirolimus rescuetherapy for refractory rejection in renal transplantation. Transplantation (2001) 71:1579–1584.
   PubMed Web of Science ®Google Scholar
• NISHIDA S, PINNA A, VERZARO R etal.:Sirolimus (rapamycin)-based rescue treatment following chronic rejection after liver transplantation. Transplant. Proc. (2001) 33:1495.
   Google Scholar
• SNELL GI, LEVVEY BJ, CHIN W et al: Rescue therapy: a role for sirolimus in heart and lung transplant recipients. TransplarM Proc. (2002) 33:1084–1085.
   Web of Science ®Google Scholar
• PAPPAS PA, WEPPLER D, PINNA AD et al.: Sirolimus in pediatric gastrointestinal transplantation: the use of sirolimus for pediatric transplant patients with tacrolimus-related cardiomyopathy. PedMtr TransplanL (2000) 4:45–49.
   PubMedGoogle Scholar
• HIDALGO M, ROWINSKY EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy: Oricogerre (2000) 19:6680–6686.
   Google Scholar
• VASQUEZ EM: Sirolimus: a new agent for prevention of renal allograft rejection. Am. Health Syst. Pharm. (2000) 57:437–448.
   PubMed Web of Science ®Google Scholar
• NAKAMURA S, SUGITA M, TANAKA S et al.: Enhanced production of in vitro tumour necrosis factor-alpha from monocytes in Behcet's disease. Nippon Ganka. Cakkai. Zasshi. (1992) 96:1282–1285.
   PubMedGoogle Scholar
• NAKAMURA S, YAMAKAWA T, SUGITA M et al.: The role of tumour necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest. Ophthalmol Vis. Sri. (1994) 35:3884–3889.
   PubMed Web of Science ®Google Scholar
• FREYSDOTTIR J, LAU S, FORTUNE F: Gammadelta T-cells in behcet's disease (BD) and recurrent aphthous stomatitis (RAS). Chu. Exp. Immurrol (1999) 118:451–457.
   PubMed Web of Science ®Google Scholar
• ROSENBAUM JT, ANGELL E: Paradoxical effects of IL-10 in endotoxin-induced uveitis: Immurrol (1995) 155:4090–4094.
   Google Scholar
• SMITH JR, HART PH, PARISH CR et al.: Experimental melanin-induced uveitis in the Fisher 344 rat is inhibited by anti-CD4 monoclonal antibody, but not by mannose-6-phosphate. Chu. Exp. Immurrol (1999) 115:64–71.
   PubMed Web of Science ®Google Scholar
• NAMBA K, OGASAWA K, KITAICHI N et al.: Amelioration of experimental autoimmune uveoretinitis by pretreatment with pathogenic peptide in liposome and anti-CD40 ligand monoclonal antibody. Immurrol (2000) 165:2962–2969.
   Google Scholar
• YATO H, MATSUMOTO Y: CD56+ T-cells in the peripheral blood of uveitis patients. Br. Ophthalmol (1999) 83: 1386–1388.
   PubMed Web of Science ®Google Scholar
• MAMO JG, AZZAM SA: Treatment of Behcet's disease with chlorambucil. Arch. Ophthalmol (1970) 84: 446–450.
   PubMed Web of Science ®Google Scholar
• MAMO JG: Treatment of Behcet's disease with chlorambucil. A follow up report. Arch. Ophthalmol (1976) 94:580–583.
   PubMed Web of Science ®Google Scholar
• CARNAHAN MC, GOLDSTEIN DA: The use of immunosuppressive drugs in uveitis. Dev. Ophthalmology: uveitis update. (1999) 31: 132–159.
   PubMedGoogle Scholar
• KIJLSTRA A: Cytokines: their role in the uveal disease. Eye (1997) 11: 200–205.
   PubMed Web of Science ®Google Scholar
• SMITH KR, LEVINSON RD, HOLLAND GN et al.: Differential efficacy of tumour necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. (2001) 45: 252–257
   PubMed Web of Science ®Google Scholar
• SFIKAKIS PP, THEODOSSIADIS PG, KATSIARI et al.: Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet (2001) 358:295–296.
   PubMed Web of Science ®Google Scholar
• SEIDER N, BEIRAN I, SCHARF J et al.: Intravenous immunoglobulin therapy for resistant ocular Behcet's disease. Br Ophthalmol (2001) 85:1287–1288.
   PubMed Web of Science ®Google Scholar
• Prevalence and incidence of diabetes. In Diabetes in America, 2'd edition. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
   Google Scholar
• DICK A, SHARMA V, LIVERSIDGE J: Single dose intranasal administration of retinal autoantigen generates a rapid accumulation and cell activation in draining lymph node and spleen: implications for tolerence therapy. Br I Ophthalmol (2001) 85: 1001–1006.
   PubMed Web of Science ®Google Scholar
• JIANG HR, TAYLOR N, DUNCAN L et al.: Total dose and frequency of administration critically affect success of nasal mucosal tolerence induction. Br. Ophthalmol (2001) 85: 739–744.
   PubMed Web of Science ®Google Scholar
• QUEEN C, SCHNEIDER WP, CELIAC HE et al.: A humanized antibody that binds to the interleukin-2 receptor. Proc. Natl. Acad. Sci. USA (1989) 86:10029–10033.
   PubMed Web of Science ®Google Scholar
• VICENTI F, KIRKMAN R, LIGHTS etal.: Interleukin-2 receptor blockade with Daclizumab to prevent acute rejection in renal transplantation: daclizumab triple therapy study group. N Engl. j Med. (1998) 228:161–165.
   Google Scholar
• WEINER HL, MACKIN GA, MATSUI M et al.: Double-blind pilot trial of oral tolerence with myelin antigens in multiple sclerosis. Science (1993) 259:1321–1324.
   PubMed Web of Science ®Google Scholar
• TRENTHAM DE, DYNESIUS-TRENTHAM RA, ORAV EJ etal.: Effects of oral administration of type 11 collagen on rheumatoid arthritis. Science (1993) 261:1727–1730.
   Google Scholar
• SANBORN GE, ANAND R, TORTI RE et al.: Sustained-released ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an intravitreal device. Arch. Ophthalmol (1992) 110: 188–195.
   PubMed Web of Science ®Google Scholar
• ANAND R, NIGHTINGALE SD, FISH RH et al.: Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch. Ophthalmol (1993) 111:223–227.
   PubMed Web of Science ®Google Scholar